The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1587
ISSUE 1587
December 16, 2019
Letermovir (Prevymis) for CMV Prophylaxis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
December 16, 2019 (Issue: 1587)
The FDA has approved letermovir (Prevymis – Merck),
a cytomegalovirus (CMV) DNA terminase complex
inhibitor, for prophylaxis of CMV infection and disease
in CMV-seropositive adult recipients of an allogeneic
hematopoietic cell transplant (HCT). Letermovir is
the first CMV DNA terminase complex inhibitor to
be approved in the US and the only drug specifically
indicated for CMV prophylaxis in HCT patients. It is not
approved for treatment of CMV infection.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Letermovir (Prevymis) for CMV Prophylaxis
Article code: 1587c
Electronic, downloadable article - $45
Article code: 1587c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
